Ketoconazole

Generic Name
Ketoconazole
Brand Names
Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
Drug Type
Small Molecule
Chemical Formula
C26H28Cl2N4O4
CAS Number
65277-42-1
Unique Ingredient Identifier
R9400W927I
Background

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...

Indication

Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions
Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
Associated Therapies
-

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-08-20
Last Posted Date
2014-01-08
Lead Sponsor
Bayer
Target Recruit Count
18
Registration Number
NCT01925638

A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants

First Posted Date
2013-08-16
Last Posted Date
2017-06-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
36
Registration Number
NCT01924299
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

CC-223 and Ketoconazole Drug-Drug Interaction Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-07-11
Last Posted Date
2019-11-12
Lead Sponsor
Celgene
Target Recruit Count
14
Registration Number
NCT01896323

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

First Posted Date
2013-04-19
Last Posted Date
2019-03-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
30
Registration Number
NCT01836198
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States

GSK239512 DDI Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-03-04
Last Posted Date
2017-07-26
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
22
Registration Number
NCT01802931
Locations
🇦🇺

GSK Investigational Site, Randwick, New South Wales, Australia

Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-02-08
Last Posted Date
2017-03-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT01787032
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-01-04
Last Posted Date
2014-05-26
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
16
Registration Number
NCT01760642
Locations
🇰🇷

Seoul National Universtiy Hospital, Seoul, Korea, Republic of

Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-10-16
Last Posted Date
2013-05-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT01707940
Locations
🇩🇪

1313.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2024. All Rights Reserved by MedPath